ADIR, a Servier Group company Clinical Trials
Sponsors / ADIR, a Servier Group company
32 ClinicalTrials.gov entries name ADIR, a Servier Group company as the lead sponsor. The portfolio currently includes 0 recruiting studies, 4 active non-recruiting studies, and 21 completed studies. 7 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include business or strategic decisions, safety concerns. Cumulative planned enrollment across all listed trials is 4,244 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
32
Total Trials
0
Recruiting
4
Other Active
21
Completed
7
Terminated / Withdrawn
4,244
Total Enrollment
Termination reasons: Business57% · Safety43%
Recent Terminations
- Acute Lymphoblastic Leukemia"Sponsor decision"
- Advanced Solid Tumor"Sponsor decision"
- Relapsed or Refractory Acute Myeloid Leukemia"The study was prematurely terminated on 14th March 2023 for strategic considerations due to the limited efficacy seen with this treatment in monotherapy. This decision was not based on any safety concerns."
- Metastatic Colorectal Cancer"Sponsor decided to discontinue the study during the Lead-In part and the Phase III part was not started due to strategic reasons."
- Dyslipidemias"for strategic reasons"
- Autism Spectrum Disorder (ASD)"The 6-month efficacy analysis did not show any significant difference between bumetanide versus placebo in the treatment of ASD in the overall studied population. No unexpected safety concerns were identified."
- Autism Spectrum Disorder (ASD)"The 6-month efficacy analysis did not show any significant difference between bumetanide versus placebo in the treatment of ASD in the overall studied population. No unexpected safety concerns were identified."
Active Trials (4 total)
- Solid Tumor PHASE1NCT05162755
- Metastatic Colorectal Cancer PHASE3NCT03869892
- Advanced Lymphoid Leukemia PHASE1NCT02735083
- Acute Myeloid Leukemia PHASE1/PHASE2NCT04742101
Top Conditions
Metastatic colorectal cancer (6) Acute lymphoblastic leukemia (4) Acute myeloid leukaemia (2) Acute myeloid leukaemia (aml) (2) Autism spectrum disorder (asd) (2) Metastatic pancreatic cancer (2) Acute myeloid leukemia (1) Advanced lymphoid leukemia (1) Advanced solid tumor (1) B-cell non-hodgkin lymphoma (nhl) (1)